Boehringer Ingelheim to sponsor American College of Cardiology-Led Diabetes Collaborative Registry

Additional support demonstrates commitment to ensuring patients get the right care at the right time

Contact: Nicole Napoli,, 202-375-6523

WASHINGTON (Jul 22, 2015) -

The American College of Cardiology has announced that Boehringer Ingelheim is the newest industry sponsor of The Diabetes Collaborative Registry, an interdisciplinary effort led by the College in partnership with the American Diabetes Association, the American College of Physicians, the American Association of Clinical Endocrinologists and the Joslin Diabetes Center.

“Heart disease is the leading cause of death for people with diabetes,” said American College of Cardiology President Kim Allan Williams, M.D., FACC. “Their unique needs call for cross-specialty care that will be made possible through the Diabetes Collaborative Registry, and we thank Boehringer Ingelheim for joining the effort to support the continued, accelerated growth of this registry.”

Since the official launch of the Diabetes Collaborative Registry just one year ago, interest and participation in the program has exceeded expectations.  To date, more than 100 cross-specialty practice entities have enrolled in the registry, expanding an already robust national footprint spanning nearly 500 practice locations with 1,300 providers across 28 states.

Additional support will allow the registry to scale up and increase its impact, including outreach to and enrollment of a larger installation base of practices and health systems, enhanced quality improvement performance reports delivered to participants, and more data collection to drive actionable insights and decision-making to improve the quality of care delivered to the right patients at the right time.

The Diabetes Collaborative Registry aspires to create the largest single repository of real-world clinical information on diabetes and cardiometabolic care in the world to improve the quality of life for all people living with these conditions.

Patients with diabetes often receive treatments across multiple medical specialties for a multitude of related conditions. The Diabetes Collaborative Registry will allow for a longitudinal study of diabetes across all stages of the disease—including presentation, progression, management and outcomes—even as patients receive treatment from multidisciplinary care teams, and it will incorporate the growing number of patients with diabetes in the ACC’s PINNACLE Registry, which is the nation’s largest ambulatory cardiovascular registry.

“BI has a long standing commitment to improving the lives of patients, and we take great pride in partnering with the ACC on this important initiative,” said Sabine Luik M.D., senior vice president, medicine and regulatory affairs, Boehringer Ingelheim Pharmaceuticals, Inc.  “As a research-driven pharmaceutical company we have great hope that the Diabetes Collaborative Registry will generate new insights into this complicated condition that can ultimately lead to improvements in cardiometabolic care.”

Participation in the registry is expected to yield long-term benefits for practices, providers and patients, as physicians can track adherence and performance against evidence-based national metrics and benchmarks at the provider, practice and site level through regular reports received; can identify potential areas to target for quality improvement opportunities; may meet requirements for federal incentive reporting programs, such as the Centers for Medicare and Medicaid Services Physician Quality Reporting System and Electronic Health Care Record Incentive Program; and will, ultimately, transform the quality of care provided to patients across the continuum of ambulatory primary and specialty care.

Researchers will have the opportunity to gather insights from this repository of diabetes care data from various providers in outpatient settings, and patients will benefit from their physicians’ increased access to a central repository of diabetes data based on the latest science and research that can be used to tailor their care. The Diabetes Collaborative Registry maintains an aggressive outcomes research agenda and is anticipated to complete a number of research abstracts and manuscripts by the conclusion of this year.

AstraZeneca is the founding industry sponsor of The Diabetes Collaborative Registry. The registry initiative continues to actively seek additional partners and supporters, including but not limited to those from industry, academia, specialty societies, patient groups, international organizations and non-traditional collaborations. Additional partners are expected to join in the coming months. For more information, visit

The American College of Cardiology is a 49,000-member medical society that is the professional home for the entire cardiovascular care team. The mission of the College is to transform cardiovascular care and to improve heart health. The ACC leads in the formation of health policy, standards and guidelines. The College operates national registries to measure and improve care, provides professional medical education, disseminates cardiovascular research and bestows credentials upon cardiovascular specialists who meet stringent qualifications. For more information, visit


< Back to Listings